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Abstract
Dengue virus (DENV) is a pathogen with a high impact on human health. It replicates in a wide range of cells involved in the
immune response. To efficiently infect humans, DENV must evade or inhibit fundamental elements of the innate immune
system, namely the type I interferon response. DENV circumvents the host immune response by expressing proteins that
antagonize the cellular innate immunity. We have recently documented the inhibition of type I IFN production by the
proteolytic activity of DENV NS2B3 protease complex in human monocyte derived dendritic cells (MDDCs). In the present
report we identify the human adaptor molecule STING as a target of the NS2B3 protease complex. We characterize the
mechanism of inhibition of type I IFN production in primary human MDDCs by this viral factor. Using different human and
mouse primary cells lacking STING, we show enhanced DENV replication. Conversely, mutated versions of STING that cannot
be cleaved by the DENV NS2B3 protease induced higher levels of type I IFN after infection with DENV. Additionally, we show
that DENV NS2B3 is not able to degrade the mouse version of STING, a phenomenon that severely restricts the replication of
DENV in mouse cells, suggesting that STING plays a key role in the inhibition of DENV infection and spread in mice.
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Introduction
Viral infections have a vast impact on human health, resulting
in hundreds of thousands of deaths yearly. To replicate and
spread, these intracellular pathogens subvert the host cellular
defense machinery. Dengue virus (DENV) is the most prevalent
arbovirus in humans, and productively infects cells that are
involved in the immune response, such as monocytes, B cells,
macrophages and dendritic cells (DCs) among others [1,2,3,4,5].
Like most viruses, DENV has evolved in order to inhibit or evade
different aspects of the innate immune system, the first line of
human defense against microbes. DCs are antigen presenting cells
(APCs) and some of the first cells that interact with the virus after
the bite of an infected mosquito. Infection of these cells induces
their activation, which results in their migration to the lymph
nodes where the virus can infect other susceptible cells. The
kinetics of infection of different cells in the immune system is not
well documented, due to the lack of immune-competent mouse
models for dengue disease. Nevertheless, in mice defective for type
I IFN signaling, one of the most accepted current models for
dengue disease, it has been shown that DCs and macrophages are
productively infected by DENV [3,4,5,6] reviewed in [7].
DENV is a single stranded RNA virus of positive polarity that,
after entering the cytoplasm of the host cell, releases its genome
and synthesizes a polyprotein using the cellular machinery, as a
first event of the viral cycle. The DENV polyprotein is cleaved by
the viral protease complex (NS2B3) and cellular proteases,
including furin [8]. After this processing, some of the viral proteins
have the ability to rearrange the ER membrane and create the
micro-environment necessary for the production of de novo
synthesized viral genomic RNA. During this event, DENV
accumulates products with conserved molecular structures, like
RNA with 59-triphosphate moiety or double stranded RNA, also
referred to as pathogen associated molecular patterns (PAMPs).
These foreign molecules are ligands of different cellular receptors
engaged in their recognition, known as pattern recognition
receptors (PRRs). PRRs are mainly divided into two different
classes depending on their localization, associated with either the
membrane or the cytoplasm. The Toll-like receptor (TLR) family
is composed of membrane proteins with domains that are designed
to detect extracellular PAMPs. On the other hand, the cytosolic
DExD/Hbox RNA helicase proteins that contain caspase-recruit-
ing domains (CARDs), referred to as RIG-I and MDA-5, can
detect specific PAMPs present in the cytoplasm. These last two
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cytoplasmic sensors together with the TLR family members
(TLR3/TLR7/TLR8) have been described so far as the most
relevant DENV sensors [9,10,11]. After recognition of the
mentioned PAMPs by the C-terminal helicase domain of RIG-I
and MDA-5, these undergo a conformational change that exposes
their CARD domains and promote the interaction with different
down-stream molecules. One of the most well studied down-
stream molecules, referred as IPS-1 (also known as, MAVS,
CARDIF or VISA), is located in the outer membrane of the
mitochondria and transmits the signal via different molecules,
including the tumor necrosis factor receptor associated factors 6
and 3 (TRAF6 and TRAF3) and the IkB kinase (IKK) family
members (TBK1, IKKa, IKKb and IKKe) among other cellular
factors [reviewed in [12]]. Recently three different groups, using
cDNA library screening of genes that induced the IFNb promoter,
described an adaptor protein that localizes in the endoplasmic
reticulum (ER). This protein was named as stimulator of the
interferon gene (STING) [13], mediator of IRF3 activation
(MITA) [14] and endoplasmic reticulum IFN stimulator (ERIS)
[15]. Also the same protein, referred to as MYPS, was previously
identified as a mediator of anti-major histocompatibility complex
II monoclonal antibody-induced apoptosis in B-lymphoma cells
[16]. STING is highly expressed in several immune cells, including
macrophages and DCs, as well as endothelial and epithelial cells
[13]. This protein can interact with RIG-I and IPS-1, but not with
MDA-5, and the signaling mediated by this adaptor is indepen-
dent of the sensing by the TLR family members [17]. In two
recent reports, it was documented that STING is involved in the
pathway that mediates the detection of pathogens with DNA
genomes [18] and has a role as a direct sensor of cyclic di-
nucleotides, a signaling molecule produced exclusively by bacteria
and archea [19]. Activation of STING by some of these stimuli
leads to its relocalization with TBK1 from the ER to perinuclear
vesicles containing the subunit of the exocyst complex 5 (Sec5)
followed by the phosphorylation of TBK-1 and the subsequent
activation of the transcription factors IRF3/7 and NFkB, which
translocate to the nucleus and complex with ATF2/c-Jun to
induce the expression of type I IFN and pro-inflammatory
cytokines [17].
A remarkable hallmark of highly virulent human pathogens is
the ability, acquired through evolution, to inhibit this innate
immune response by the expression of viral factors that affect one
or several steps of the above described signaling cascade. Some of
the most notorious examples are the influenza virus NS1 protein,
that targets RIG-I for degradation, minimizing the sensing of
influenza virus PAMPs by this PRR [20] or the Hepatitis C virus
NS34A protease complex that cleaves the adaptor IPS-1 to
interrupt the signaling that ends with the activation of IRF3,
NFkB and the subsequent production of type I IFN in human
hepatocytes [21].
Our group has documented that DENV is a weak inducer of
type I interferon in human DCs, in particular when compared
with other viruses that competently produce these cytokines in
large amounts, such as Newcastle disease virus (NDV) [22] and
Semliki Forest virus (SFV) [23]. This lack of type I IFN production
by DCs infected with DENV results in an impaired ability of those
DCs to prime T cells toward Th1 immunity, an effect that can be
reversed by the addition of IFNb [24]. Nevertheless, DENV is able
to induce the expression of some pro-inflammatory cytokines at
early times post infection, which we hypothesize is a strategy used
by this virus to attract more cells to the site of infection by allowing
the expression of some chemo-attractants by infected cells. Our
group described that the infection by DENV does not induce the
phosphorylation of IRF3 in human primary cells, resulting in an
inhibition of type I IFN production [24]. In a subsequent report,
we examined the ability of DENV-infected DCs to respond to a
variety of type I IFN-triggering signals using potent stimulators
such as NDV, SeV, SFV, or TLR-3 ligand poly(I:C) [25]. This
effect is viral dose dependent and takes place as early as 2 hours
after DENV infection. We also showed that the inhibition of
IFNa/b production after NDV infection in DENV-infected DCs is
not a bystander effect, implying an active role of the DENV-
infected DC population in the inhibition of IFNa/b. By using an
NDV vector strategy to express the individual DENV non-
structural proteins (NS2A, NS2B3, NS4A and NS4B), we showed
that only the recombinant NDV expressing the protease complex
NS2B3 inhibited IFNa expression in infected MDDCs, as
compared to NDV alone. Similar results were obtained using an
IFNb promoter activity assay in 293T cells. Catalytically inactive
NS2B3 mutants showed a diminished inhibition of this phenotype,
which highlighted the important role for the protease activity of
the NS2B3 protein as inhibitor of the type I IFN production.
Interestingly, the proteolytic core of NS2B3, consisting of the last
40 amino acids of NS2B and the first 180 amino acids of NS3, was
enough to reduce the activation of the IFNb promoter by a strong
stimulus, such as Sendai virus (SeV) infection.
DENV has also been shown to express inhibitors of the type I
IFN signaling cascade [26] and has been shown to encode for at
least four non-structural proteins NS2A, NS4A, NS4B and NS5
that target different components of this pathway. The most
remarkable example is the proteasomal degradation of human
STAT2 by the NS5, a phenomenon that does not occur in mouse
cells, which makes mouse STAT2 a restriction factor for DENV
replication in these animals [27,28,29,30,31]. In summary, DENV
can successfully inhibit two fundamental steps of the innate
immune system, both the inhibition of the type I IFN production
and the signaling. In this way, DENV reduces the expression of
hundreds of interferon inducible genes that would otherwise
establish the antiviral state and control the spread of the infection
in the host.
In the present report, we describe the mechanism of inhibition
of type I IFN production by DENV in primary human and mouse
cells and identify the human adaptor molecule STING as a target
Author Summary
Dengue virus (DENV) is a pathogen with a high impact in
human health that replicates in a wide range of cells of the
immune system. To efficiently infect humans, DENV must
evade or inhibit fundamental elements of the innate
immune system, namely the type I interferon response
(IFN). Thus, DENV can inhibit type I IFN signaling
(described by several groups), and type I IFN production
(described by our group). We documented the inhibition
of type I IFN production in human monocyte derived
dendritic cells (MDDCs) with an otherwise strong cytokine
and chemokine profile in those cells and that the NS2B3
protease complex of DENV functions as an antagonist of
type I IFN production, and its proteolytic activity is
necessary for this event. Here we identify the human
adaptor molecule STING as a target of the NS2B3 protease
complex and characterize the mechanism of inhibition of
the type I IFN production in primary human MDDCs
mediated by this viral factor. We also describe that DENV
NS2B3 cannot degrade the mouse version of STING, a
phenomenon that strictly restricts the replication of DENV
in mouse cells, suggesting that STING plays a key role in
the inhibition of DENV infection and spread in mice.
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of the DENV NS2B3 protease complex. We demonstrate that the
proteolytic activity of this viral factor is crucial for the cleavage and
degradation of STING and this phenomenon impairs the
production of type I IFN in DENV infected cells. Furthermore,
we show that DENV NS2B3 is not able to cleave the mouse
version of STING. Using STING double knockout mouse
embryonic fibroblast (MEFs) and human dendritic cells, we
demonstrate the relevant role of this host factor in the restriction
of DENV replication in mouse cells. This is the first report
showing STING as a target for cleavage and degradation by a
viral protein to inhibit innate immune responses and as a host
restriction factor for virus infection in primary cells.
Results
Dengue virus NS2B3 protease complex cleaves human
STING
Previous results from our laboratory showed that dengue virus
inhibits type I IFN production in human primary dendritic cells
and that this inhibition requires a proteolytically active NS2B3
protease complex [24,25].
In order to identify potential NS2B3 targets we performed a
bioinformatic search for potential DENV protease cleavage sites
contained within members of the type I IFN pathway [32]. We
identified putative cleavage sites in several known members of the
type I IFN pathway (see table 1). After testing the factors shown in
table 1 for their susceptibility to be cleaved by the DENV protease
NS2B3, we observed that only STING was cleaved in our
experimental set up (data not shown and figure 1). We have
generated a wild type DENV-NS2B3, and a proteolytically
inactive version (NS2B3-S135A), (Figure 1A) by direct mutagen-
esis [25] that were used to analyze the potential cleavage of
STING by the DENV protease complex. When we compared the
human amino acid sequence of human STING to its mouse
counterpart we noticed that the putative NS2B3 cleavage site in
hSTING which is situated at the beginning of transmembrane
domain 3 (Figure 1B), is absent in mouse STING. In order to test
the susceptibility of human and mouse STING proteins to
proteolytic cleavage or degradation, we co-expressed a C-
terminally HA-tagged STING alongside a wild type or catalyti-
cally active DENV-NS2B3, and a proteolytically inactive version
(NS2B3-S135A) in 293T cells, (Figure 1A) and analyzed them by
western blot (Figures 1C, 1D). In the presence of WT NS2B3 we
observed the full-length 42 kDa human STING and an additional
band of about 32 KD, which is consistent with a C-terminal region
product of a cleavage occurring within the first 96 aa of STING
(Figure 1C). The additional band was not visible when the mouse
version of STING or a catalytically inactive NS2B3 was used
(Figure 1C and 1D). This putative cleavage site for the DENV
NS2B3 lies very close to the conserved cysteine motif C88xxC91,
or redox motif, recently described to be required for dimerization
of STING and subsequent signaling in the type I IFN production
pathway [33]. Regardless of their susceptibility to cleavage by the
DENV NS2B3 complex, both the human and mouse versions of
STING co-immunoprecipitated with the WT DENV NS2B3
complex and the proteolytically inactive mutant NS2B3 S135A
(Figure 1E, lanes 2, 3, 6 and 7). To map the putative cleavage site
of human STING for the DENV NS2B3 complex, we mutated
the sequence corresponding to the first three amino acids of the
human site, RRG (shown in figure 1B as hSTING in red) with
the sequence corresponding to the amino acids HCM found in
the mouse version of STING (shown in figure 1B as mSTING).
These recombinant versions of STING were co-transfected into
293T cells with the WT and mutant version of the NS2B3
protease and the ability of the DENV protease to cleave STING
(Figure 1F, lane 5) was drastically reduced when the mouse
sequence was present in hSTING (Figure 1F, lane 2). These data
confirm the requirement for amino acids RRG for efficient
cleavage of STING by the DENV NS2B3. However, replace-
ment of the corresponding amino acid sequence of mouse
STING (IHCM) by the human putative cleavage sequence
(LRRG) does not render mouse STING susceptible to cleavage
by the DENV protease (Figure 1G, lane 2), suggesting that
additional flanking amino acids are required for this cleavage.
Altogether, these results strongly suggest that STING is a target
for NS2B3 in human cells and possibly a restriction factor for
DENV infection in the mouse.
To test whether endogenous STING undergoes the same
NS2B3-dependent processing as in overexpression experiments in
293T cells, we infected human MDDCs with DENV-2 (16681
strain) and analyzed the cell lysates by western blot at different
time points (Figure 1H). Infection of MDDCs by DENV resulted
in the degradation of STING that could be detected at 24 and
48 hours post infection (hpi) (Figure 1H, lanes 9 and 10) which
correlate with peak expression levels of the NS2B3 (as detected
with NS3 specific antibodies). As expected, this degradation of
STING was not observed in MDDCs treated with UV-inactivated
DENV or mock treated cells (Figure 1H, lanes1–5 and 11–15).
These data demonstrate that DENV NS2B3-dependent cleavage
of endogenous human STING occurs in cells relevant to DENV
infection (MDDCs), and therefore has the potential to play a
crucial role in inhibition of type I IFN production.
DENV NS2B3 inhibits induction of IFNb and p55-C1B
promoters by human STING
We next investigated whether STING cleavage by DENV
NS2B3 had an impact on its ability to mediate the signaling
necessary for type I IFN production. We transfected 293T cells
with either hSTING (Figures 2A and 2B) or mSTING (Figures 2C
and 2D) and the three different versions of the DENV protease:
wild type, the proteolytically inactive version (NS2B3-S135A) and
the proteolytic core (NS2Bh-NS3pro) alongside luciferase report-
er constructs driven by either an IFNb promoter (IFNb-Luc) or
by three IRF3/7 binding sites (p55-C1B-Luc) (kindly provided by
Dr. Megan Shaw and shown in figure 2E schematically) [34]. As
shown in figures 2A and 2B, cleavage of hSTING by the DENV
NS2B3-WT and NS2Bh-NS3pro greatly inhibited its ability to
activate both reporter constructs, while transfection of the mutant
version of the protease did not. Conversely, the DENV NS2B3
Table 1. List of putative targets of DENV protease.
Host Factor Putative Cleavage site for DENV NS2B3
IRF3 RAGQWLWA QR LG HCHTYWAVS
IRF7 LRGPQLWA RR MG KCKVYWEVG
TLR3 YKLNHALCL RK GM FKSHCILNWP
TBK1 TLLLYQELM RK GI RWLIELIKDD
IKKe PPIAPYPSP TR KD LLLHMQELCE
RIG-I VGNVIKMIQ TR GR GRARGSKCFL
STING VRACLGCPL RR GA LLLLSIYFYYSL
Human factors involved in type I IFN production, harboring putative cleavage
sites for DENV NS2B3 protease complex based on Li et al. 2005 [33]. Amino
acids shown in bold in the middle column represent the putative target
sequences for cleavage by the DENV NS2B3.
doi:10.1371/journal.ppat.1002934.t001
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had minimal or no impact on the ability of mSTING to induce
activation of either of the reporter constructs used. We did not
observe any DENV NS2B3-dependent inhibition when the
human adaptor TBK1 was used as a positive control to induce
the IFNb promoter, demonstrating that the inhibition during
dengue infection occurs upstream of this adaptor (data not
shown). Taking together, these data demonstrate that cleavage of
hSTING by the DENV NS2B3 precludes the induction of type I
IFN responses. Moreover, to validate the observed results in
human primary cells, we used E. coli DNA, a known inducer of
STING signaling [35] to treat human MDDCs previously
infected with DENV, UV-inactivated DENV or mock treated
(as shown schematically in figure 2F). Figures 2G, 2H and 2I
show that only live DENV but not UV inactivated DENV was
able to inhibit the induction of IFNb, IFNa or ISG15 by this
ligand in human MDDCs.
DENV NS2B3 antagonizes type I IFN production in human
but not in mouse cells
To validate the results described using p55-C1B and IFNb
promoter assays in a primary cell model, we measured IFNa/b
production upon infection of MDDCs either with DENV or a
Semliki forest virus (SFV) expressing the DENV NS2B3 protease
complex or the mutant version of the protease (NS2B3-S135A) as
a control [23,25]. Consistent with our earlier report [24], human
MDDCs infected with DENV-2 (16681 strain) were unable to
produce IFNa/b. Furthermore, SFV-NS2B3 induced significantly
lower levels of IFNa/b mRNA than the SFV-NS2B3-S135A
(Figures 3A and 3B). Interestingly, SFV-NS2B3-WT induced
significantly higher expression of TNFa at early times post-
infection compared to SFV-NS2B3-S135A control (Figure 3C). As
shown previously, this would suggest an involvement of the NS2B3
protease complex in the expression of this pro-inflammatory
Figure 1. DENV NS2B3 protease complex cleaves human STING but not mouse STING. (A) Schemes of the DENV-NS2B3 protease
constructs used [wild type (WT), proteolyticaly inactive mutant (S135A) and proteolytic core (NS2Bh-NS3pro)]. (B) Representative map of the human
adaptor STING showing the five transmembrane domains (TM) presented at the N-terminal region. Highlighted aminoacid sequence alignment of
human and mouse STING at the N-termini of TM3 (light blue), and cleavage site of DENV NS2B3 (highlighted in red). (asterisk) indicates positions
which have a single, fully conserved residue. (C) Co-transfection of DENV-NS2B3 plasmid constructs and human STING expressing plasmid in 293T
cells. The samples were analyzed by SDS-PAGE and detected by Western blotting (WB). (D) Same co-transfection experiment described in (C) but
using mouse STING expression plasmid. (E) Analysis of the interaction between DENV-NS2B3 protease and STING by co-immunoprecipitation assay.
HA-tagged NS2B3 and FLAG-tagged human and mouse STING plasmids were transfected in 293T cells. After 48 h, cells lysates were prepared and
immunoprecipitation was carried out using anti-FLAG antibody. (F) Evaluation of cleavage ability of DENV-NS2B3 on WT human STING and mutant
version of human STING harboring aminoacids sequence from mouse STING (RRG/HCM) by WB using anti-HA and anti-FLAG antibodies. (G)
Evaluation of cleavage ability of DENV-NS2B3 on WT mouse STING and mutant version of mouse STING harboring aminoacids sequence from human
STING (IHCM/LRRG) by WB using anti-HA antibodies. (H) Degradation of endogenous human STING by DENV in primary human DCs analyzed by WB
of endogenous levels of human STING and DENV NS3 protein in human DCs infected with MOCK, DENV and UV-DENV at different times post
infection using anti-STING and anti-NS3 antibodies described in materials and methods.
doi:10.1371/journal.ppat.1002934.g001
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cytokine [24]. As expected, the infection of MDDCs by DENV up-
regulated the expression of STING in these cells (Figure 3D).
Figure 3E shows the kinetics of infection by DENV in MDDCs,
with the peak of viral RNA at 48 hpi. In contrast, the SFV vectors
used in these studies show low levels of viral RNA at late times
after treatment (Figure 3F), since these vectors are replication
deficient [36]. Then we infected mouse bone marrow-DCs (BM-
DCs) using the same viruses, and analyzed the gene induction
profile in those cells. As expected, infection of BM-DCs by DENV
was rapidly controlled, consistent with the inability of DENV to
infect mouse cells, and showed an opposite kinetic of viral RNA
synthesis compared to the observed pattern in human DCs, with a
modest induction of cytokines (Figure 3G to 3K). SFV is an
alphavirus that can replicate in mouse cells, and DCs in particular.
In this context, the SFV-NS2B3 exhibited a higher induction of
both IFNa/b genes compared to the SFV-NS2B3-S135A control,
showing an opposite profile than that observed in human DCs, in
which SFV-NS2B3-S135A induced higher levels of IFNa/b genes
(Figure 3G and 3H). Again, the kinetics of infection of the SFV
vectors in mouse DCs (Figure 3L) show very low levels of viral
RNA, consistent with their lack of productive infection in these
cells [36]. The observed phenomenon agrees with the inability of
recombinant DENV-NS2B3 to cleave mouse STING and
decrease the activity of the IFNb and p55-C1B promoters induced
by this adaptor protein (Figure 2C and 2D).
STING strongly restricts the replication of DENV in mouse
cells
To explore STING’s impact on the DENV replication in mouse
cells, we used WT (Sting +/+) and STING double knockout (Sting2/2)
mouse embryonic fibroblasts (MEFs). First, we infected WT and
Sting 2/2 MEFs with two different DENV-2 strains, 16681 and
NGC (a strain that was obtained after several passages in mouse
brain) [37], with an MOI of 5. Then, we measured the ability of the
two DENV-2 strains to induce IFNb production, to replicate in
these cells and to release infectious particles from those cells
(Figure 4A–4F). Both DENV-2 strains induced significantly higher
levels of IFNb in WT MEFs as compared to the Sting 2/2 MEFs
(Figure 4A and 4D), underlining the relevance of STING in the
signaling of type I IFN upon the infection with DENV. Consistent
with the observed low induction of IFNb, Sting 2/2 MEFs were
permissive to DENV replication while, despite the high MOI used,
replication of DENV 16681 and NGC was rapidly controlled in WT
MEFs (Figure 4B and 4E). The production of infectious particles by
Figure 2. DENV NS2B3 inhibits induction of IFNb and p55-C1B promoters by human STING. (A) 293T cells were co-transfected with a
vector encoding for an IFNb promoter driving the luciferase gene, a plasmid encoding for human STING, and plasmids for different versions of DENV
protease (see Fig. 1D). Luciferase activity was measured 24 hours after transfection. (B) Same as described in (A) but using a plasmid encoding for the
mouse version of STING. (C) 293T cells were co-transfected with a vector encoding for p55-C1B promoter driving the luciferase gene, a plasmid
encoding for the human STING and plasmids for three different version of the DENV protease (see Fig. 1D). (D) Same as described in (C) but using a
plasmid encoding for the mouse version of STING. (E) Scheme of the luciferase expressing vectors used, harboring the promoters for IFNb and p55-
CIB (F) Scheme of experimental design. MDDCs were treated with MOCK, DENV and UV inactivated DENV. After 12 hours, the three sets of cells were
stimulated with MOCK or purified E. coli DNA and total RNA was purified at 2 and 7 hours post treatment. Relative expressions of type I IFN and ISGs,
normalized against rsp11 and a-tubulin, were measured by qRT-PCR at specific time points. (G) INFb mRNA. (H) IFNa mRNA. (I) ISG15 mRNA. Data
shown represents one of two independent experiments. Error bars are the standard deviation of two individual replicates. *, p,0.05.
doi:10.1371/journal.ppat.1002934.g002
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the two DENV-2 strains in WT and Sting 2/2 MEFs was measured
by plaque assay and shows that the KO MEFs were more permissive
to DENV infection than the WT MEFs and have very different
peaks of infection (Figure 2C and 2F). To test whether our
observation was independent from the high MOI and viral strains
used, we repeated the infection using different DENV serotypes
(DENV-2 16681 strain, DENV-3 PR-6 strain and DENV-4 H-241
strain) and an MOI of 1, with similar results (data not shown). These
results are likely due to the inability of DENV to inhibit the type I
IFN signaling in mouse cells and the establishment of the antiviral
state [31]
Mutation of cleavage site for DENV-NS2B3 restores the
ability of STING to induce type I IFN production upon
DENV infection
To confirm the relevance of STING cleavage by the DENV-
NS2B3 on the inhibition of type I IFN production upon DENV
infection, we transduced Sting 2/2 MEFs with lentiviruses
expressing either WT human STING (STING-WT) or a mutant
(uncleavable) version, that harbors the mouse STING sequence at
the NS2B3-cleavage site (STING-MUT) (Figure 1B and 1F).
Twenty-four hours after transduction MEFs were infected with
DENV-2 at an MOI of 1 (strains 16681 and NGC) or mock
treated and the levels of IFNb, IFNa and viral RNA were
measured by qRT-PCR after total RNA extraction from the cells
at different times post infection (Figure 5A–5F). A schematic
representation of the lentiviruses used is shown in figure 5G. For
these experiments, as shown in figure 5A and 5D, MEFs
expressing the uncleavable version of STING (STING-MUT)
expressed significantly higher levels of IFNb mRNA when
compared to MEFs expressing WT STING (STING-WT) or to
the control MEFs (GFP) confirming that the cleavage of STING
by DENV-NS2B3 is necessary for the inhibition of IFNb
production in infected cells. The induction of IFNb was detected
as early as 2 hpi. Infection with the two DENV-2 strains also
induced higher levels of IFNa mRNA in MEFs expressing
STING-MUT than in the MEFs expressing STING-WT and
the GFP control (Figure 5B and 5E). Under these experimental
conditions, the replication of the mouse adapted DENV-2 (NGC)
was increased in Sting 2/2 MEFs expressing wild type STING as
compared with STING-MUT (Figure 5F). In the case of 16681
strain, a significant increase of replication was observed only with
Sting 2/2 MEFs (GFP) at 48 hpi., and no significant difference was
observed in MEFs expressing the two versions of STING,
presumably due to a high level of lentiviral-expressed STING
that could overwhelm the ability of this non mouse-adapted
DENV strain to replicate in this system (Figure 5C).
Expression of STING-MUT in primary human DCs
attenuates DENV replication
As shown in figure 5, the lack of STING cleavage was sufficient
to increase the expression of type I IFN in MEFs infected with
Figure 3. DENV NS2B3 inhibits type I IFN production in human but not in mouse dendritic cells. Human dendritic cells were infected
with MOCK, DENV-2 (16681), SFV-NS2B3-WT and SFV- NS2B3-S135A using a MOI = 1, and total RNA was extracted at 2, 6, 12, 24, 48 and 72 hpi (A to F).
Relative expressions of different proteins and viral RNAs were measured by qRT-PCR at specific time points normalized against rsp11 and a-tubulin.
(A) INFb mRNA. (B) IFNa mRNA. (C) TNFa mRNA. (D) STING mRNA and (E) DENV RNA, (F) SFV RNA. (G to L) Mouse dendritic cells were infected with
MOCK, DENV, SFV-NS2B3-WT and SFV- NS2B3-S135A using an MOI = 1, and total RNA was extracted at 2, 6, 12, 24, 48 and 72 hpi. Relative amounts of
mRNA were measured by qRT-PCR using 18S and b-actin as housekeeping genes. (G) IFNbmRNA. (H) IFNamRNA. (I) TNFamRNA. (J) STING mRNA. (K)
DENV RNA (L) SFV RNA. Data re representative of three independent experiments from three different donors (A to F) and two individual experiments
(G to L). Error bars indicate standard deviations of the mean from duplicate samples.*, p,0.05.
doi:10.1371/journal.ppat.1002934.g003
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DENV. To validate these results in primary human cells, we
transduced MDDCs from three different donors with the STING-
expressing lentiviruses and the GFP-only control (Figure 5G).
STING transduced DCs were then infected with DENV-2 at an
MOI of 5 and we assessed the production of IFNb in those cells.
As shown in Figure 6A (showing one representative donor out of
three), there were no significant differences between the levels of
STING-WT and STING-MUT mRNA. This demonstrates that
any difference in antiviral effect observed with the two different
versions of STING is independent of the expression levels for these
proteins. Upon DENV-2 infection, DCs expressing STING-MUT
produced higher levels of IFNb when compared with STING-WT
or GFP controls (showing statistical significance at 2 and 12 hpi).
The induction of IFNb messenger RNA was detected as early as
2 hpi, which is in agreement with the results described with MEFs
(Figures 4, 5 and 6B). These data confirm that detection of DENV
infection by DCs takes place at early times post infection and that
STING cleavage by DENV NS2B3 is fundamental to inhibit the
signaling mediated by this adaptor in human cells. We next
measured DENV replication kinetics and we found that viral RNA
levels were significantly lower in DCs over-expressing STING-
MUT when compared with STING-WT and GFP control
(Figure 6C). Suggesting that the inability of DENV to cleave
mutant STING and inhibit the induction of type I IFN has a direct
impact on its replication kinetic and the accumulation of viral
RNA in those cells.
STING silencing in primary human cells increases DENV
replication
To determine STING’s impact on DENV replication in
primary human MDDCs, we used RNA interference (RNAi) to
silence its endogenous expression. A decrease of STING mRNA
level was observed when specific siRNAs were used compared to
two scrambled control siRNAs (Figure 7A). As expected, the
previously observed upregulation of STING after DENV infection
was controlled by the STING siRNAs (Figure 7A). As a
consequence, the reduction in STING expression resulted in an
increase of DENV replication, illustrated in Figure 7B. When the
viral progeny released by those infected MDDCs was quantified by
plaque assay, the six donors treated with STING specific siRNA,
showed viral production under this experimental conditions,
however when scrambled siRNA was used, only three out of the
six donors released detectable viral progeny in the supernatant
(Figure 7C). Data shown in figures 7A and 7B correspond to donor
4 in figure 7C. Taken together, these data confirm that STING is
a crucial restriction factor of DENV replication in human
dendritic cells, since its silencing increases the levels of DENV
replication in those cells.
Several human immune cells fail to produce type I IFN
after DENV infection
Different populations of cells were isolated from human blood
and subsequently infected with DENV-2 at MOI of 1 and 12 h
after infection supernatants were collected and RNA was extracted
from cells. DENV-2 RNA was detected in all cells tested including
plasmacytoid DCs (pDCs), B cells, blood circulating DCs (cDCs),
monocytes as well as in monocyte-derived DCs (MDDCs)
(Figure 8A). We also analyzed the cytokine and chemokine
expression profile in all those cells by qRT-PCR (data not shown)
and by multiplex ELISA (Figure 8B) in the supernatants at 12 hpi.
We observed a marked chemokine response (IL-8 and MIP1b) in
monocytes, MDDCs, B cells and cDCs at this early time point,
(Figure 8B). However pDCs did not show any significant
chemokine profile after DENV-2 infection at this time point
Figure 4. STING restricts replication of DENV in mouse cells. Sting +/+ and Sting 2/2 MEFs were infected with DENV-2 (16681 strain) (A, B and
C) and DENV-2 (NGC strain) (D, E and F) at an MOI of 5 and total RNA was extracted at the indicated times post infection. Levels of IFNb were
measured by ELISA(A and D) and DENV RNA levels were measured by qRT-PCR (B and E) using 18S and b-actin for normalization.. Infectious particles
released to the supernatants of infected MEFs were measured by plaque assay on BHK cells (C and F) as described in materials and methods. Data are
representative of two independent experiments. Error bars represent standard deviations of the mean of two replicate samples. *, p,0.05.
doi:10.1371/journal.ppat.1002934.g004
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(Figure 8B). More interestingly, there was no significant type I IFN
production observed in any of the cells tested by qRT-PCR (data
not shown) or ELISA (Figure 8B). These data suggest that there is
a coordinated and distinct kinetic of infection of DENV-2 in
different cell populations in blood and there is a lack of type I IFN
production in those cells after infection with this virus, at least at
this early time point. The early time point of 12 hpi was chosen to
obtain sufficient numbers of pDCs, since these cells have short
half-lives and downregulate their specific cell surface markers in a
rapid fashion. Nevertheless, we have previously reported that as
early as 8 hpi, pDCs are able to produce type I IFN after infection
with other viruses, such as NDV [24].
To rule out that the lack of type I IFN production resulted from
lack of cell to cell interactions, we infected whole PBMCs with
DENV-2 (MOI of 1) and 18 h after infection cell supernatants
were collected. Figure 8C shows multiplex ELISA data of cell
supernatants from those cultures. While there is a clear IL-8
response to DENV-2 infection in PBMCs, consistent with the
strong IL-8 signature observed in sera from patients [38], there
was no detectable IFNa secretion from infected PBMCs
(Figure 8C). This suggests that DENV-2 may inhibit type I IFN
production in susceptible cells within those cultures.
Macrophages have been shown to support DENV infection in
animal models, and have been proposed to play an important role
during early phases of dengue virus infection [39,40]. We tested if
monocyte-derived macrophages (MDMs) when infected with
DENV were able to produce type I IFN. Figure 8D shows that
macrophages are efficiently infected with DENV, with an early
peak of replication and produce TNFa and IL-6 after DENV
infection and after SFV expressing the WT and mutant versions of
the NS2B3 DENV protease complex (Figures 8E, 8F). Under these
experimental conditions we were unable to detect IFNa released
by macrophages after DENV infection. Interestingly, when
compared to MDDCs infected with the same viruses (Figure 8H),
macrophages produce at least 10-fold lower levels of IFNa after
SFV infection, and the inhibitory effect of the DENV protease in
this system was less apparent (8G and 8H).
Discussion
Activation of innate immunity due to the detection of viral
replication products in the cell leads to the expression of
hundreds of antiviral genes that controls the spread of the
infection [12]. The inhibition of different steps implicated in these
molecular pathways by viruses has been a matter of extensive
study for several years. It has been demonstrated by others and
by our group that DENV can inhibit both the production and
signaling of type I IFN by the expression of viral proteins. In this
Figure 5. Expression of mutant STING in Sting 2/2 MEFs rescues their ability to produce type I IFN and to control DENV infection.
Two versions of recombinant human STING (WT and MUT) and GFP control were expressed in Sting 2/2 MEFs using lentiviral vectors (described in
materials and methods). After 24 hours, infection by lentivirus was confirmed by GFP expression and MEFs were subsequently infected with DENV-2
16681 (A–C) or DENV-2 NGC (D–F). Total RNA was extracted at the specified times post infection and the levels of IFNb mRNA (A and D), IFNa mRNA
(B and E), and DENV RNA (C and F) were measured by qRT-PCR. (G) Schematic representation of lentiviral vectors used in these experiments. Error bars
represent standard deviations of the mean of two replicate samples.*, p,0.05.
doi:10.1371/journal.ppat.1002934.g005
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way, DENV can mitigate the immune response induced by the
host upon infection [24,25,29]. Here we have identified the
human adaptor molecule STING as a protein with a predom-
inant role in the recognition of DENV by the innate immune
system. This adaptor protein was described to reside in the ER, a
cellular organelle intimately related to the DENV replication
process. Also, STING has been described as part of the TRAP
(translocon associated protein) complex that can associate with
RIG-I and IPS-1, two proteins with relevant roles in viral
detection [41]. Ishikawa et al. also described an inhibition of the
STING mediated IFNb production by the yellow fever virus
(YFV) NS4B [42]. However, when we tried to replicate these
results using the DENV NS4B, this viral protein was unable to
decrease the induction of luciferase mediated by STING in an
IFNb promoter assay (data not shown).
By co-expression experiments of human STING with the
DENV NS2B3 protease complex we observed a specific cleavage
at (94-RRGA-99), a site described as a putative target for DENV
NS2B3 [32] that generated a cleaved band of approximately
32 KDa (Figure 1C and 1F). Interestingly, by analysis of the
sequence alignment between human STING and its mouse
version we, observed a drastic difference in the amino acid
sequence in this region (94-HCMA-99) (shown in figure 1B) and
the inability to cleave the mouse STING by the DENV NS2B3
was confirmed by co-expression experiments (Figure 1D and 1G).
Furthermore, the impact that the STING cleavage by NS2B3 had
on the signaling of IFNb production pathway was subsequently
demonstrated using IFNb and p55-C1B promoter systems
(Figure 2). In these experiments, a reduction in luciferase induction
was only observed for human STING, suggesting that the cleavage
confirmed by WB (showed in Figures 1C and 1F) impaired the
ability of this adaptor to induce IFNb. Recently, Jin et al.
described a series of mutations in hSTING that were implicated in
the activation/dimerization and subsequent induction of interfer-
on. Interestingly, two cysteines located at C88XXC91 were
fundamental for the proper induction of type I IFN after
stimulation [33]. It could be interesting to investigate the presence
of mutations at the cleavage site of STING for DENV NS2B3 in
the human population, to identify a natural resistance to DENV
infection.
While this manuscript was under review, Yu and colleagues
reported by overexpression experiments that the DENV protease
can cleave the adaptor molecule MITA, [43]. In the present report
we provide important data on the role of this adaptor molecule in
primary human and mouse cells and during the context of DENV
infection. We also confirmed the cleavage and degradation of
STING by the DENV NS2B3 protease in human MDDCs in the
context of DENV infection, since it is important to validate these
findings in a relevant primary cell system and during virus
infection (Figure 1H). In primary human cells as well as in mouse
cells, such as MEFs and DCs, we also found that the presence of
human STING allowed for greater DENV replication and the
presence of mouse STING seemed to restrict DENV replication
(Figure 3, figure 4 and figure 7). We also show that the NS2B3
protease of DENV has specificity for the human STING and not
for the mouse homologue of this protein (Figure 5 and figure 6),
suggesting that STING may be an important restriction factor in
mice.
Figure 6. Over expression of STING in MDDCs potentiates IFNb induction and attenuates DENV replication. Primary human monocytes
were transduced with lentiviruses expressing either STING-WT, STING-MUT or GFP as a control (Figure 5G and materials and methods). After five days
of culture in the presence of GMCSF and IL-4 (see materials and methods) the differentiated MDDCs, were infected with DENV-2, 16681 using an MOI
of 5 and total RNA was extracted at the specified times post infection. (A) Levels of STING mRNA were measured for mock and DENV infected cells at
2, 6, 12, 24 and 48 hpi. (B) Levels of mRNA for IFNb were measured as indicated for (A). (C) Replication of DENV as measured by qRT-PCR (materials
and methods) using specific primers for DENV-2 at the specified times post infection. Data shown are representative of three individual experiments
from three independent donors. Error bars represent the standard deviation of the mean of two replicate samples. *, p,0.05.
doi:10.1371/journal.ppat.1002934.g006
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Several viral proteases have been described as proteins that
modulate cellular pathways, allowing many viruses to modify the
intra and extracellular environment to promote optimal conditions
for replication and spread. Some of the most remarkable
characteristics observed at early times after infection by DENV
are the lack of IFNa/b induction and a robust induction of pro-
inflammatory cytokines like TNFa [24,25]. As it was described in
our previous work, DENV infection can abrogate IRF3 phos-
phorylation, but has no impact on NF-kB activity [25]. Using
recombinant viruses expressing DENV-NS2B3 we observed a
clear effect on the induction of TNFa in human DCs, similar to
that observed with DENV infection (Figure 3 and figure 8). Also,
the inhibition of luciferase activity driven by p55-C1B promoter
was considerably more efficient when compared with IFNb-
promoter, since p55-C1B only harbors sites for IRF3/7 transcrip-
tion factors, and IFNb-Luc has also has response elements for NF-
kb and AP-1 transcription factors (Figures 2B and 2D). Further-
more, Ishikawa et al. overexpressed STING in 293T cells in the
presence of different promoters driving the luciferase gene.
Interestingly, STING stimulated IFNb promoter up to 400-fold,
IRF3 response element (PRDIII-I-Luc) up to 1,000-fold, and NF-
kb responsive promoter (NF-kb-Luc) only up to 12-fold [41]. This
observation suggested that STING is fundamentally involved in
phosphorylation of IRF3, and under these experimental conditions
showed a 100 fold less influence on NF-kb induction. Taken
together, these observations suggest that DENV NS2B3 protease
inhibits IFNb production by cleavage of the adaptor STING
without modifying the observed NF-kb activity induced after
infection by DENV. Further work exploring the impact that
DENV-NS2B3 has on the induction of NF-kb activity in infected
cells would confirm a putative role of this viral factor in the
modulation of innate immune response by the induction of pro-
inflammatory cytokines, a hallmark phenomenon observed during
infection by DENV [44].
It is becoming increasingly clear that STING is a crucial
adaptor in immune cells after infection with different viruses, such
as HIV and DENV, among others [35,45,46]. These viruses
require activation of their target cells in order to establish
infection, or in the case of DENV to induce viremia in the host.
Nevertheless, all viruses need to limit or inhibit the production of
type I IFN in infected cells to avoid the establishment of an
antiviral state in those cells. STING could be instrumental in these
types of virus infections, since it can discriminate between the
induction of type I IFN and the activation of the NFkB pathway.
Along those lines, this report shows a novel mechanism of
inhibition of IFN production by an RNA virus, namely DENV
targeting STING. By inhibiting only type I IFN but not the NF-kB
pathway, DENV induces a specific profile in infected human
MDDCs and other susceptible primary cells that allow the virus to
efficiently reach the lymph nodes and spread in the infected host,
culminating in the production of viremia. All our experiments
were performed in the context of primary infections with DENV,
since we believe that the early events in primary infections dictate
the quality of adaptive immune responses and the outcome of the
infection. By targeting DCs and inhibiting the production of type I
IFN in those cells, DENV may be able to efficiently modulate the
generation of adaptive immune responses and establish infection in
the host [24,25].
It has been proposed that during DENV infection IPS-1 may be
responsible for controlling early viral replication and type I IFN
production [47], while the IFN signaling pathway (JAK/STAT)
may control late viral replication and type I IFN production in
DENV infected cells [48]. It is possible that interactions between
STING and IPS-1 [46] may be disrupted by the DENV NS2B3
targeting of STING. This mayinhibit type I IFN production early
during DENV infection in susceptible cells, although the NS2B3
has not been shown to directly interact with IPS-1. Further
experiments are required to understand these complex interplays
between different signaling molecules in human primary cells
infected with DENV.
Figure 7. Silencing of STING in human MDDCs results in
enhanced DENV replication. Primary human MDDCs were trans-
fected with two scramble siRNAs and three STING specific siRNAs as
described in the materials and methods section. 48 hours post
transfection, cells were mock or DENV-2 infected (16681)at an MOI of
1. (A) Levels of mRNA for STING were quantified by qRT-PCR at the
specified times post infection. (B) Levels of DENV RNA were measured at
24 hpi by qRT-PCR (data from donor 4 is shown). (C) DENV titers were
determined by plaque assay of the supernatants from infected MDDCs
treated with scramble and STING siRNA from six independent donors at
24 hpi (ND: not detected). Under these experimental conditions the
limit of detection for the plaque assay was 101 PFU (indicated with a
dashed line). Data for A and B is representative of six independent
donors tested in 3 separate experiments. Error bars represent the
standard deviation of the mean of two replicate samples.
doi:10.1371/journal.ppat.1002934.g007
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Our experiments demonstrate that primary human cells
implicated in dengue virus infection, such as dendritic cells,
macrophages, monocytes and B cells can support DENV
replication, although at different levels. Interestingly, DENV
infection did not induce type I IFN production in any of those
human primary cells tested (Figure 8). These different blood cells
may play different roles during DENV infection in humans, such
as being involved in the initial infection or in the final stage of
viremia. Also, since the mouse models that support DENV
replication and recapitulate dengue symptoms are deficient in type
I IFN responses or are reconstituted with human immune cells
[6,49], the inhibition of type I IFN in infected cells seems to be
crucial for the establishment of infection by DENV. Our data on
different cells from blood also show that the inhibition of type I
IFN production by DENV is not a DC specific phenomenon
(Figure 8).
The inability of DENV to replicate in wild type mouse cells is
well documented, and many attempts have been made to develop
a competent animal model to study DENV infection [50]. The
data presented in this manuscript, showing the ability of DENV to
replicate in Sting 2/2 MEF (Figure 4), open new approaches to
develop a mouse model to study DENV infection and also
highlights the requirement that type I IFN production has on the
innate immune system and for the control of invading pathogens.
Ashour et al. described the adaptor STAT2 as a restriction factor
for DENV replication in mouse cells [31]. Based on our combined
data, an interesting approach would be the development of a
transgenic mouse model with humanized STING and STAT2.
This approach could provide an immune competent mouse model
for DENV that eliminates two of the potential bottlenecks that
exist for DENV replication in mice.
Materials and Methods
Ethics statement
The animal protocol used in this study was reviewed and
approved by the University of Miami Institutional Animal Care
and Use Committee (IACUC) under IACUC protocol 11–181
‘‘Host Defense and the Regulation of Interferon Production:
STING.’’
The University of Miami has an Animal Welfare Assurance on
file with the Office of Laboratory Animal Welfare (OLAW),
Figure 8. Human primary immune cells from blood fail to produce type I IFN after DENV infection. Several cell populations (pDCs, B
cells, cDCs, Monocytes and MDDCs) were isolated from human blood as described in material and methods and subsequently infected with DENV-2
(166810 at MOI of 1. (A) viral RNA levels were measured in each cell population 12 h after infection by qRT-PCR using specific primers for DENV-2. (B)
Cell supernatants from samples described above were collected to measure cytokine and chemokine levels by multiplex ELISA. (C) Whole PBMCs
were infected with DENV-2 at MOI of 1 (black bars) or uninfected (grey bars) after ficoll centrifugation. Cytokine and chemokine levels in the PBMC
supernatants were measured at 18 h post infection by multiplex ELISA. Monocyte derived macrophages (MDMs) (materials and methods) were
infected with DENV-2 (16681) or SFV-NS2B3-WT and SFV- NS2B3-S135A at an MOI = 1 or mock infected for the indicated times. (D) DENV RNA levels
were measured by qRT-PCR at the indicated times. Cytokines present in the supernatants from those infected MDMs were measured by multiplex
ELISA: (E) TNFa levels, (F) IL-6 levels and (G) IFNa levels. (H) MDDC were infected with DENV as described for D to G and IFNa levels were measured in
the supernatants by multiplex ELISA at the indicated times. Data shown for each graph are representative of three individual experiments from three
independent donors. Error bars represent the standard deviation of the mean of three replicate samples.
doi:10.1371/journal.ppat.1002934.g008
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National Institutes of Health. The assurance number is #A-3224-
01, effective July 11, 2007. Additionally, as of July 20, 2010, the
Council on Accreditation of the Association for Assessment and
Accreditation of Laboratory Animal Care (AAALAC Internation-
al) has continued the University of Miami’s full accreditation.
Cell lines
Vero, 293T and mouse embryonic fibroblast (MEFs), were
cultured in Dulbecco’s modified essential medium (DMEM)
supplemented with 10% fetal bovine serum (FBS). Baby hamster
kidney cells (BHK) were grown in Glasgow minimal essential
medium (MEM) supplemented with 10% FBS, and 20 mM
HEPES. Mosquito cells derived from Aedes albopictus, clone C6/36,
were expanded at 33uC in RPMI medium with 10% FBS. All
media were supplemented with 100 U/ml of L-glutamine and
100 mg/ml of penicillin-streptomycin. All tissue culture reagents
were purchased from Invitrogen.
Viruses
Dengue virus serotype 2 (DENV-2) strains 16681 and New
Guinea C were used in this study. DENV was grown in C6/36
insect cells for 6 days as described elsewhere [51]. Briefly, C6/36
cells were infected at a multiplicity of infection (MOI) of 0.01, and
6 days after infection, cell supernatants were collected, clarified,
and stored at 80uC. The titers of DENV stocks were determined
by limiting-dilution plaque assay on BHK cells [52]. Semliki Forest
virus (SFV) expressing GFP and DENV-NS2B3 were generated as
described previously [36] and titrated in BHK cells by immuno-
fluorescence [53].
Lentiviral vector constructs were built using conventional
molecular biology techniques. Briefly, human STING cDNA
was PCR amplified from pcDNA3.1 hSTING [13] and cloned
into a lentiviral vector derived from pHR SIN CSGW [54]
(Figure 5G). Mutations in the NS2B3 cleavage site at positions 94–
96 of hSTING were obtained by overlap PCR. Residues RRG
were changed to the corresponding murine sequence HCM.
Lentiviral vector derived viruses were obtained by transfection
of HEK 293T with 3 plasmids encoding STING, HIV-1 Gag-Pol,
and VSV-G respectively [55]. Viral supernatants were harvested
48 and 72 hours post-transfection, 0.45 mm filtered, concentrated
at 14,000 g for 6 hours over a 20% sucrose cushion and frozen at
280uC until used.
Isolation of different populations of cells from blood
Monocytes, pDCs, B cells and circulating CD11c+ DCs (cDCs)
were isolated from blood of healthy donors (New York Blood
Center) using Miltenyi isolation kits. CD14+ clinimacs, for
monocytes, CD123/BDCA4 kit for pDCs and BDCA1 kit for
cDCs. B cells were isolated as part of the BDCA1 kit for isolation
of cDCs according to manufacturers’ instructions. The purity of
each cell population was tested by flow cytometry as described
below and was routinely 85–95% for CD14+ cells, 87–90% for
pDCs, and 95–99% for both MDDCs and cDCs.
Infection of PBMCs or individual populations of cells from
blood
Samples of 56105 isolated cell populations were infected with
DENV-2, 16681 at the indicated MOI in a total volume of 100 ml
of DC media for 1 hour at 37 C. Then, DC media supplemented
with 4% HS was added up to a final concentration of 106 cells/ml
and cells were incubated for the remainder of the infections at
37 C. At the indicated times, cell supernatants were collected and
cell pellets were used for RNA extractions. Whole PBMCs were
used after ficoll centrifugation and samples of 606106 PBMCs
were infected with DENV-2 at MOI of 1 or left uninfected. After
1 hour DC media 4% HS was added. Eighteen hpi supernatants
were collected and isolation of the different cell populations after
DENV-2 infection was carried out as described above.
Generation of monocyte-derived dendritic cells (MDDCs)
and monocyte derived macrophages (MDMs)
Human MDDCs were obtained from healthy human blood
donors (New York Blood Center), following a standard protocol as
previously described [24] and described above. Briefly, after Ficoll-
Hypaque gradient centrifugation, CD14+ cells were isolated from
the mononuclear fraction using a MACS CD14 isolation kit
(Milteny Biotec) according to the manufacturer’s directions.
CD14+ cells were then differentiated to naı¨ve DCs by incubation
during 5 to 6 days in DC medium (RPMI supplemented with
100 U/ml L-glutamine, 100 g/ml penicillin-streptomycin, and
1 mM sodium pyruvate) with the presence of 500 U/ml human
granulocyte-macrophage colony-stimulated factor (GM-CSF) (Pe-
proTech), 1,000 U/ml human interleukin 4 (IL-4) (PeproTech),
and 10% FBS (Hyclone). To generate MDMs, monocytes were
cultured in the presence of 2000 U/ml human granulocyte-
macrophage colony-stimulated factor (GM-CSF) for 10 days, and
media was replenished (with same concentration of GMCSF) at
days 2, 5 and 8. The purity of each cell population was confirmed
by flow cytometry analysis and was at least 99% for MDDCs and
95% for MDMs.
Generation of mouse bone marrow-derived dendritic
cells
Femurs and tibia of wild-type C57BL/6 mice (Jackson) were
soaked in 70% ethanol, washed with RPMI (Invitrogen), and
epiphyses were cut to expose the bone marrow. The bones were
flushed with RPMI supplemented with 10% fetal bovine serum
(FBS) to extract the bone marrow. Cells were pelleted by
centrifugation, washed once with RPMI and resuspended in
ammonium chloride red blood cell lysis buffer. RBC lysis was
performed for 1 minute at room temperature, stopped with
RPMI-FBS and cells were collected by centrifugation. Bone
marrow cells were seeded in 6-well dishes in RPMI containing
10% FBS, 50 U/ml Penicillin (Invitrogen), 50 mg/ml Streptomy-
cin (Invitrogen), 20 ng/ml GM-CSF (Peprotech), 10 ng/ml IL-4
(eBioscience), and 40 mM beta-mercaptoethanol (BIO-RAD). Cells
were cultured for 5 days at 37 degrees C, 5% CO2 and fresh
media was added every 2–3 days.
Dengue infection of MDDCs
Human and mouse DCs were obtained as described above, and
at day 5 of culture, samples of 16106 cells were resuspended in
100 ml of DC-medium and were infected for 45 min at 37uC with
the indicated MOI of virus (diluted in DC media) or with DC
medium (mock group) in a total volume of 200 ml. After the
adsorption period, DC medium supplemented with 10% FBS was
added up to a final volume of 1 ml, and cells were incubated for
the appropriate time at 37uC.
siRNA transfection and Dengue infection of human
MDDCs
2.56104 MDDCs were seeded per well in 96 well plates and
transfected with the corresponding siRNA using the StemFect
RNA transfection kit (Stemgent), according to the manufacturer
instructions. Chemically synthesized 27mer siRNA duplexes were
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obtained from OriGene Technologies, Inc. The sequences of the
STING siRNA oligonucleotides used in this study are as follows:
siSTING -1:59-rGrGrCrArUrGrGrUrCrArUrArUrUrArCrAr-
UrCrGrGrArUAT-39.
siSTING-2:59-rArCrCrUrGrUrGrArArArUrGrGrGrArUrCr-
ArUrArArUrCAC-39.
siSTING-3:59-rGrGrArUrUrCrGrArArCrUrUrArCrArArUr-
CrArGrCrArUTA-39.
Two random non-coding control siRNA were used: Sc-1 (59-
rUrArCrGrUrArCrUrArUrCrGrCrGrCrGrGAT-3) from Qia-
gen, and Sc-2 (universal scrambled negative control siRNA duplex
SR30004) from OriGene Technologies, INC. 48 h after transfec-
tion, cells were infected with Dengue virus at an MOI of 1. Briefly,
cells were centrifuged (4006g, 10 min), the media was removed
and 25 ml of RPMI containing the appropriate amount of virus
was added and the plates were incubated for 45 min at 37uC.
Then, 75 ml of RPMI with 10% FBS were added and cells were
incubated at 37uC for the indicated hours. Subsequently, cells
were recovered by centrifugation for 10 min at 4006g, and the
cell pellets were lysed for RNA isolation.
Transduction of human MDDCs
Plated monocytes were transduced as previously described [56].
In brief, freshly isolated monocytes were transduced with VSV-G
pseudo-typed SIV VLPs and each lentiviral vector construct for
3 h by spinoculation, in the presence of 2 mg/mL polybrene
(Sigma). Subsequently, cells were washed, resuspended in regular
growth medium described before for the generation of monocytes
derived human dendritic cells and incubated for 5 days at 37uC
until stimulation. At day 5 post-transduction, MDDCs were
infected with DENV as described before, and cell pellets were
collected at the indicated time points, and lysed for RNA isolation.
Reporter analysis
293T cells were transfected by using Lipofectamine 2000
reagent (Invitrogen) according to the manufacturer’s protocol. A
type I IFN production antagonist assay was performed as
described previously [25] using IFNb-Luc and p55-C1B-Luc
[34,57]. 293T cells seeded on 24-well plates were transiently
transfected with 50 ng of the luciferase reporter plasmid together
with a total of 400 ng of various expression plasmids or empty
control plasmids. As an internal control, 50 ng pRL-TK was
transfected simultaneously. Then, 24 or 48 h later, the luciferase
activity in the total cell lysate was measured by using the Dual-
Luciferase Reporter Assay System (Promega) according to the
manufacturer’s directions.
Western blot analysis
Transfection of 293T cells and infection of human DCs was
performed as described above. Cell lysates were obtained after
incubation of cells with RIPA lysis buffer (Sigma Aldrich)
supplemented with complete protease inhibitor (Roche) and
resuspended in a total of 50 ml of Laemmli sample buffer (Bio-
Rad). Crude lysates were either boiled for 10 min or incubated at
42uC for 20 min and then kept on ice. Each sample was loaded in
a polyacrylamide-SDS gel, and the proteins were electrophoret-
ically separated by conventional methods. Proteins were trans-
ferred to nitrocellulose, and blots were incubated with anti-HA,
anti-FLAG, anti-Actin anti-GAPDH (Sigma Aldrich) and rabbit
polyclonal antibodies anti-hSTING [41] and anti-DENV NS3
(kind gift of Dr. Andrea Gamarnik), and developed using SNAP
ID detection system (Millipore), following the manufacturer’s
instructions. Antibody-protein complexes were detected using a
Western Lighting chemiluminescence system (Perkin Elmer).
RNA isolation
RNA from different cells was extracted using Trizol (Invitro-
gen), followed by a treatment with DNase using DNA-free
Ambion. The concentration was evaluated in a spectrophotometer
at 260 nm, and 500 ng of RNA were reverse transcribed using the
iScript cDNA synthesis kit (Bio-Rad) according to the manufac-
turer’s instructions.
qRT-PCR
Evaluation of the expression of human and mouse cytokines
from different cell types and viral RNA was carried out using iQ
SYBR green Supermix (Bio-Rad) according to the manufacturer’s
instructions. The PCR temperature profile was 95uC for 10 min,
followed by 40 cycles of 95uC for 10 s and 60uC for 60 s.
Expression levels for individual mRNAs were calculated based on
their CT values using two different housekeeping genes (human:
rps11 and a-tubulin genes) and (mouse: S18 and b-Actin) to
normalize the data.
Statistical analysis
One paired two tailed Student’s t-test was used to analyze data.
Data considered significant demonstrated p values less than 0.05.
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